+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07323056

Study of Sacituzumab Tirumotecan and Limertinib as Pre-Surgery Treatment for Locally Advanced EGFR-Mutant Non-Small Cell Lung Cancer

Led by Shanghai Pulmonary Hospital, Shanghai, China · Updated on 2026-01-07

36

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the use of sacituzumab tirumotecan combined with limertinib as a conversion therapy for patients with locally advanced, potentially resectable non-small cell lung cancer NSCLC that has EGFR mutations. This Phase 2, single-arm exploratory study aims to provide stronger clinical evidence for improving treatment methods and to find biomarkers that may help predict how well the combination therapy works, enabling more precise treatment choices for patients with this type of lung cancer. Participants will receive sacituzumab tirumotecan intravenously every two weeks for a total of six doses, alongside daily oral limertinib for 12 weeks. After completing this neoadjuvant treatment, patients will undergo enhanced chest CT scans and other evaluations to determine if radical surgery is feasible. Those eligible will proceed to surgery, while others will have their treatment plan discussed further by a multidisciplinary team. Throughout the study, patients will be monitored for the rate of complete pathological response in the perioperative period. Additional outcomes such as major pathologic response, objective response rate, event-free survival, overall survival, R0 resection rate, treatment-related adverse events, and discontinuation rates due to adverse events will also be assessed up to five years. The total study duration involves treatment, surgery if applicable, and long-term follow-up for survival and safety outcomes.

CONDITIONS

Brief Title

Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

Research Team

P

Peng Zhang, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here